Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486572 · ClinicalTrials.gov registry record · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
A NA study of Cirrhosis and Carcinoma, Hepatocellular, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 4,700
- Enrollment target
- 17
- Study locations
NCT05486572: Recruiting NA study of Cirrhosis and Carcinoma, Hepatocellular, sponsored by VA Office of Research and Development.
NCT05486572 is a NA study of Cirrhosis and Carcinoma, Hepatocellular that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 4,700 participants, below the 90,320-participant average among 53 other Cirrhosis trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486572, a NA study of Cirrhosis and Carcinoma, Hepatocellular, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 4,700 participants
- Enrollment target
- 17
- Study locations
Study Summary
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.
Primary Outcome
death due to liver cancer
Conditions Studied
Interventions
- OTHER Abbreviated Magnetic Resonance Imaging with serum AFP
- OTHER Abdominal Ultrasound Screening with serum AFP
Study Locations (17)
California
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
- VA Northern California Health Care System, Mather, CA - Sacramento
- VA San Diego Healthcare System, San Diego, CA - San Diego
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Florida
- James A. Haley Veterans' Hospital, Tampa, FL - Tampa
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Nebraska
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE - Omaha
New York
- James J. Peters VA Medical Center, Bronx, NY - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,700 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2031-09-01 |
| Phase | NA |
What NCT05486572 shows while recruiting
NCT05486572 is an interventional study that assigns participants to a tested intervention. Its 4,700 participants enrollment target places it among the larger protocols in the corpus, below the 90,320-participant average among 53 other Cirrhosis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Abbreviated Magnetic Resonance Imaging with serum AFP is the first listed.
NCT05486572 lists 17 locations in 13 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05486572 about?
NCT05486572 is a clinical study titled "Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI". The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in p...
What is the current status of trial NCT05486572?
This trial is currently recruiting. It is a NA study. The enrollment target is 4,700 participants. The study started on 2023-11-03. Estimated completion is 2031-09-01.
What conditions does trial NCT05486572 study?
This clinical trial studies the following conditions: Cirrhosis, Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT05486572?
The interventions under investigation include: Abbreviated Magnetic Resonance Imaging with serum AFP (OTHER), Abdominal Ultrasound Screening with serum AFP (OTHER).
Who is sponsoring clinical trial NCT05486572?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486572 being conducted?
This trial has 17 study locations across California, Colorado, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05486572's enrollment target sits among peer trials
4,700 2nd of 53 the highest of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
CirrhosisRx CDS System
RECRUITING · NA
-
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
RECRUITING · NA
-
Adverse Outcomes and Mortality in Liver Transplant
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
- NCT06888388 · 4,700 participants
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- NCT06535139 · 4,630 participants · NA
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI